Programmed death-ligand 1 expression in gastric cancer by the combined positive score using the PD-L1 IHC 28-8 pharmDx test: a single institution's experience.

Authors

Tomomi Hamaguchi, Kyoko Furusawa, Mamoru Watanabe, Kei Hayashi, Mitsuhiro Furuta, Yasuhiro Inokuchi, Satoshi Kobayashi, Makoto Ueno, Yuta Nakayama, Mie Tanabe, Junya Morita, Kyohei Kanematsu, Shinsuke Nagasawa, Takanobu Yamada, Takashi Ogata, Takashi Oshima, Tomoyuki Yokose, Nozomu Machida, Junji Furuse, Shin Maeda

Published in

Japanese journal of clinical oncology. Aug 28, 2026. Epub Aug 28, 2026.

Abstract

Programmed death-ligand 1 (PD-L1) Combined Positive Score (CPS) is a biomarker of nivolumab efficacy in advanced gastric cancer (AGC). Reported CPS ≥ 5 in AGC has been inconsistent across studies. We aimed to examine the distribution of CPS in real-world clinical practice using the Dako PD-L1 IHC 28-8 pharmDx (Dako 28-8) assay and to evaluate its clinical utility.
We retrospectively assessed CPS using Dako 28-8 in 138 patients with AGC treated at our institution between January 2022 and December 2022.
The numbers of patients with CPS ≥ 5, 1 ≤ CPS < 5, and CPS < 1 were 65 (47.1%), 50 (36.2%), and 23 (16.7%), respectively. Among the patients evaluated for microsatellite instability (MSI) or tumor mutation burden (TMB), MSI-high was identified in 3/32 (9.4%), 2/31 (6.5%), and 1/20 (5.0%), while TMB-high was identified in 5/14 (35.7%), 4/20 (20.0%), and 2/11 (18.2%) in the CPS ≥ 5, 1 ≤ CPS < 5, and CPS < 1 groups, respectively. Nivolumab combination therapy was administered as first-line treatment in 14, 10, and 11 patients in the CPS ≥ 5, 1 ≤ CPS < 5, and CPS < 1 groups, respectively. Median Progression-free survival was 5.6 months in CPS ≥ 5, 5.9 months in 1 ≤ CPS < 5, and 6.5 months in CPS < 1.
The frequency of CPS ≥5 in patients with AGC was approximately half of the total population. Because TMB-high tumors were identified in some patients with CPS < 5, further studies are needed to clarify the potential role of TMB in predicting ICI responsiveness in this population.

PMID:
42664280
Bibliographic data and abstract were imported from PubMed on 29 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.